Board of Directors

Kirk Dornbush

Senior Advisor and Co-Founder

Mr. Dornbush co-founded and served as Iconic’s Chief Executive Officer from 2007 until 2014. Under his leadership, Iconic advanced ICON-1, the company’s lead asset, through non-clinical development and completed a successful Phase 1 study in wet AMD. Prior to the Company’s inception in 2003, Mr. Dornbush was President of Diem Investments, a private investment advisory firm. He continues to serve as Manager of Diem Bioventures, LLC, an investor in Iconic. Mr. Dornbush has served on numerous for profit and non-profit Boards including the Board of Directors of the National Park Foundation where he chaired the Foundation’s Investment Committee. Mr. Dornbush received his B.A. in English from The Colorado College and his JD from Boston University School of Law.

Todd Foley

MPM Capital

Mr. Foley has served as a member of Iconic Therapeutics’ Board of Directors since April 2014. Mr. Foley is a Managing Director with MPM Capital, a venture capital firm, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Rhythm, Chiasma, OSS, Selexys Pharmaceuticals, and Valeritas. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

William L. Greene, MD

Chief Executive Officer

Julia P. Gregory

Julia P. Gregory is a seasoned biotechnology executive with CEO, CFO, board and investment banking skills. She has a proven track record for successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues. She has extensive experience in recruiting outstanding management teams and overcoming significant challenges. As a biotechnology executive, she has raised more than $1.5 billion for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche) and Human Genome Sciences (now GSK). Most recently, she was CEO and Board member of ContraFect, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO and Board member of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. She has been EVP Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Prior to her corporate experience, Ms. Gregory was an investment banker for over 20 years primarily as Head of Healthcare and Investment Banking at Punk, Ziegel & Company and at Dillon, Read & Co, Inc.

She received her B.A. in International Affairs from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from The Wharton School of The University of Pennsylvania.

K. Peter Hirth, PhD

Dr. Hirth has over 30 years of drug discovery and development expertise, and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, Afferent Pharmaceuticals, and Alios Biopharma. Most recently, Dr. Hirth served as co-founder and CEO of Plexxikon, Inc., where he built a novel, structure-guided drug discovery platform, which has brought several new chemical entities (NCEs) into the clinic such as Zelboraf®, which was approved by the FDA for metastatic melanoma together with a companion diagnostic. From 1991 to 2000, Dr. Hirth was with Sugen Inc., where he was instrumental in building the company from its inception, advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, Dr. Hirth was a Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval in 1989. Earlier in his career, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. He received his PhD in molecular genetics from Heidelberg University, Germany.

Johan Kördel, PhD

Lundbeckfond Ventures

Dr. Kördel is a Senior Partner with Lundbeckfond Ventures where he leads investments in the life sciences sector in the US and Europe. Previously, Dr. Kördel was co-founder and CEO of Sound Biotech ApS, and co-founder and Senior Vice President of Research and Business Development of Biovitrum (today part of SOBI). Previously, he worked at Pharmacia in leadership positions in research, early development, portfolio management, and business development. Dr. Kördel has co-founded other biotech companies and been appointed to numerous board positions both in private and public companies. He currently serves on Boards of Directors of Acacia Pharma, BoneSupport AB, Enterome SA, Ziarco, River Vision, and VHSquared. Dr. Kördel earned his PhD from Scripps Research Institute and Lund University, and completed his post-doctoral work at Harvard Medical School. He is an Associate Professor in Physical Chemistry at the University of Lund, Sweden.

Bruce Robertson, PhD

H.I.G. BioVentures

As a Managing Director at H.I.G. BioVentures, Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. He currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, Clarus Therapeutics, and Intersection Medical. Prior to joining H.I.G., Dr. Robertson served as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments, and previously was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. He started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.

Dr. Robertson is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. He holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.